BRICS countries sign agreement to collaborate on research, public health efforts

Published on January 23, 2013 at 4:47 AM · No Comments

"Health ministers of the group of developing countries known as BRICS (Brazil, Russia, India, China, and South Africa) have signed an agreement to work together on research projects and to reduce the burden of disease," BMJ reports. "Meeting in New Delhi on 10 and 11 January, they adopted the 'Delhi communiqué,' which promises greater collaboration in ensuring access to public health services and in implementing affordable, equitable, and sustainable solutions to emerging health threats," the journal writes.

"The communiqué identified several priority areas: non-communicable diseases, mental disorders, multidrug-resistant tuberculosis, malaria, and HIV and AIDS," according to BMJ. "Agreeing with the idea of thematic areas for research and development, Tanmay Mahapatra, director of medical research at the Mission Arogya Health and Information Technology Research Foundation, in Kolkata, said, 'Each of these focus areas need to be addressed with specifically targeted research planning and development to minimize the burden of ill health contributed by them,'" the journal adds (Bhaumik, 1/18).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

 

Posted in: Disease/Infection News | Healthcare News

Tags: , , , , , , ,

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Evolution of multiple sclerosis treatments: an interview with Mike Panzara, Head of MS & Neurology Clinical Development, Genzyme